MX387115B - Métodos para tratar la influenza. - Google Patents

Métodos para tratar la influenza.

Info

Publication number
MX387115B
MX387115B MX2019009443A MX2019009443A MX387115B MX 387115 B MX387115 B MX 387115B MX 2019009443 A MX2019009443 A MX 2019009443A MX 2019009443 A MX2019009443 A MX 2019009443A MX 387115 B MX387115 B MX 387115B
Authority
MX
Mexico
Prior art keywords
methods
treating influenza
prevention
treatment
relates
Prior art date
Application number
MX2019009443A
Other languages
English (en)
Spanish (es)
Other versions
MX2019009443A (es
Inventor
Carolyn Luscombe
Gary Ewart
Original Assignee
Biotron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900385A external-priority patent/AU2017900385A0/en
Application filed by Biotron Ltd filed Critical Biotron Ltd
Publication of MX2019009443A publication Critical patent/MX2019009443A/es
Publication of MX387115B publication Critical patent/MX387115B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2019009443A 2017-02-08 2018-02-07 Métodos para tratar la influenza. MX387115B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017900385A AU2017900385A0 (en) 2017-02-08 Methods of treating influenza
PCT/AU2018/050085 WO2018145148A1 (en) 2017-02-08 2018-02-07 Methods of treating influenza

Publications (2)

Publication Number Publication Date
MX2019009443A MX2019009443A (es) 2019-12-16
MX387115B true MX387115B (es) 2025-03-19

Family

ID=63106827

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009443A MX387115B (es) 2017-02-08 2018-02-07 Métodos para tratar la influenza.

Country Status (12)

Country Link
US (1) US10918623B2 (https=)
EP (1) EP3579833B1 (https=)
JP (1) JP7019727B2 (https=)
KR (1) KR102607599B1 (https=)
CN (1) CN110325187B (https=)
AU (1) AU2018218179B2 (https=)
BR (1) BR112019016316A2 (https=)
ES (1) ES2910136T3 (https=)
MX (1) MX387115B (https=)
RU (1) RU2769317C2 (https=)
SG (1) SG11201907034PA (https=)
WO (1) WO2018145148A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122020020745B8 (pt) 2010-07-22 2023-10-31 Gilead Sciences Inc Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreende
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
SI3349758T1 (sl) 2015-09-16 2022-08-31 Gilead Sciences, Inc. Postopki za zdravljenje okužb z virusom arenaviridae
US10682368B2 (en) 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
AU2018262501B2 (en) 2017-05-01 2020-12-10 Gilead Sciences, Inc. Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
JP7554841B2 (ja) 2020-03-12 2024-09-20 ギリアード サイエンシーズ, インコーポレイテッド 1’-シアノヌクレオシドを調製する方法
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
AU2021296841B2 (en) 2020-06-24 2025-01-23 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
AU2021330835B2 (en) 2020-08-24 2023-12-14 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
SI4204421T1 (sl) 2020-08-27 2024-07-31 Gilead Sciences, Inc., Spojine in postopki za zdravljenje virusnih okužb
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
EP4346772B1 (en) 2021-05-26 2026-04-01 Gilead Sciences, Inc. Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CN118574614A (zh) * 2021-11-24 2024-08-30 生物环境有限公司 治疗sars-cov-2感染的方法
IL315102A (en) 2022-03-02 2024-10-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
KR20240154646A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
PE20250419A1 (es) 2022-03-03 2025-02-14 Gilead Sciences Inc Compuestos antivirales y metodos de elaboracion y uso de los mismos
JP2025508941A (ja) 2022-03-03 2025-04-10 ギリアード サイエンシーズ, インコーポレイテッド 抗ウイルス化合物並びにその作製及び使用方法
JP2025519390A (ja) 2022-06-06 2025-06-26 ギリアード サイエンシーズ, インコーポレイテッド Sars-cov-2を含むウイルス感染の治療方法
WO2024006376A1 (en) 2022-06-29 2024-01-04 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
EP4547665A1 (en) 2022-06-30 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
WO2024173458A1 (en) 2023-02-16 2024-08-22 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
IL326322A (en) 2023-08-31 2026-04-01 Gilead Sciences Inc Antiviral compounds and methods for their production and use
US20250090537A1 (en) 2023-08-31 2025-03-20 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20250099476A1 (en) 2023-09-06 2025-03-27 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US20250109157A1 (en) 2023-09-28 2025-04-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596107A (en) 2005-06-24 2013-09-27 Biotron Ltd Antiviral compounds and methods
ES2563477T3 (es) * 2007-08-03 2016-03-15 Biotron Limited Composiciones antivirales para tratar la hepatitis C a base de 5-(1-metilpirazol-4-il)2-naftoilguanidina y 2'-C-metiladenosina o 2'-C-metilcitidina
KR101369584B1 (ko) * 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
JP7525976B2 (ja) * 2014-07-07 2024-07-31 エリアン リミテッド ライアビリティ カンパニー ウイルス予防治療方法及び曝露前予防キット
CN110870864B (zh) 2018-08-29 2021-09-24 复旦大学 马来酸卡比沙明在制备抗流感病毒药物中的应用

Also Published As

Publication number Publication date
EP3579833A4 (en) 2021-01-13
BR112019016316A2 (pt) 2020-03-31
MX2019009443A (es) 2019-12-16
JP2020506243A (ja) 2020-02-27
CA3052503A1 (en) 2018-08-16
JP7019727B2 (ja) 2022-02-15
RU2019126746A (ru) 2021-03-09
SG11201907034PA (en) 2019-08-27
RU2769317C2 (ru) 2022-03-30
US10918623B2 (en) 2021-02-16
CN110325187A (zh) 2019-10-11
KR20190112051A (ko) 2019-10-02
US20200093796A1 (en) 2020-03-26
AU2018218179A1 (en) 2019-08-22
ES2910136T3 (es) 2022-05-11
EP3579833A1 (en) 2019-12-18
AU2018218179B2 (en) 2023-05-04
KR102607599B1 (ko) 2023-11-28
CN110325187B (zh) 2022-09-30
WO2018145148A1 (en) 2018-08-16
RU2019126746A3 (https=) 2021-05-28
NZ755900A (en) 2025-03-28
EP3579833B1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
MX387115B (es) Métodos para tratar la influenza.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
EA201791576A1 (ru) Ингибитор jak
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
MD3416631T2 (ro) Agenți terapeutici pentru bolile neurodegenerative
ZA201606320B (en) Human plasma kallikrein inhibitors
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
EA201891644A1 (ru) Антибактериальные соединения и их применение
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
MX382765B (es) Tratamiento para la colangitis biliar primaria.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
PH12016502322B1 (en) Compounds and methods for preventing or treating malaria
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX374354B (es) Método de curación de heridas.
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
MX2017002093A (es) Terapia con anticuerpos para vih como sustituto de tratamiento.
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
EA202190626A3 (ru) Комбинация тразодона и габапентина для лечения боли